Mitigating Clinical Risk with Strategic Preclinical Design for DMD Exon Skipping Therapeutics

• Applying AOC platform for exon skipping in DMD as therapeutic approach
• Creating successful and translatable preclinical package for Duchenne’s

Speakers:

Barbora Malecova

Director of Biology

Avidity Biosciences, Inc.